Bowel disorders

Gastroenterology

Volumn 150, Issue 6, 2016, Pages 1393-1407.e5

  Lacy, Brian E ^a   Mearin, Fermín ^b   Chang, Lin ^c   Chey, William D ^d   Lembo, Anthony J ^e   Simren, Magnus ^f   Spiller, Robin ^g  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b CENTRO MÉDICO TEKNON   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Abdominal Pain; Bloating; Constipation; Diarrhea; Distension; Functional Bowel Disorders; Irritable Bowel Syndrome

Indexed keywords

ALOSETRON; AMITRIPTYLINE; BISACODYL; C REACTIVE PROTEIN; CALGRANULIN; CASCARA SAGRADA; CHENODEOXYCHOLIC ACID; COLESEVELAM; COLESTIPOL; CROMOGLYCATE DISODIUM; DISODIUM HYDROGEN PHOSPHATE; ELOBIXIBAT; ELUXADOLINE; LACTITOL; LACTULOSE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MAGNESIUM CITRATE; MAGNESIUM SULFATE; MANNITOL; ONDANSETRON; PICOSULFATE SODIUM; PLECANATIDE; PROBIOTIC AGENT; RAMOSETRON; SODIUM DIHYDROGEN PHOSPHATE; SORBITOL; SPASMOLYTIC AGENT; UNINDEXED DRUG;

ARTICLE; BLOOD CELL COUNT; CLINICAL EVALUATION; COGNITIVE BEHAVIORAL THERAPY; COLONOSCOPY; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; DUODENUM BIOPSY; ESOPHAGOGASTRODUODENOSCOPY; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FUNCTIONAL ABDOMINAL BLOATING; FUNCTIONAL ABDOMINAL DISTENTION; FUNCTIONAL CONSTIPATION; FUNCTIONAL DIARRHEA; GROUPS BY AGE; HEMP SEED; HUMAN; IMMUNOASSAY; IRRITABLE COLON; LEUKOCYTE COUNT; LIFESTYLE MODIFICATION; MENTAL DISEASE; META ANALYSIS (TOPIC); OPIOID NDUCED CONSTIPATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW (TOPIC);

EID: 84964758095     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.02.031     Document Type: Article

References (208)

1. R.M. Lovell, and A.C. Ford Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis Clin Gastroenterol Hepatol 10 2012 712 721
2. A.C. Ford, D. Forman, A.G. Bailey, and et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior Am J Gastroenterol 103 2008 1229 1239
3. S.L. Halder, G.R. Locke 3rd, C.D. Schleck, and et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study Gastroenterology 133 2007 799 807
4. B.M. Spiegel, R. Bolus, N. Agarwal, and et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials Aliment Pharmacol Ther 32 2010 1275 1291
5. O. Palsson, S. Heymen, and W.E. Whitehead Abdominal pain versus abdominal discomfort: implications for diagnostic assessment of irritable bowel syndrome (IBS) United Eur Gastroenterol J 2 2014 P405
6. Whitehead WE, Palsson OS. Report on Rome Normative GI Symptom Survey. 2014.
7. F. Mearin, and B.E. Lacy Diagnostic criteria in IBS: useful or not? Neurogastroenterol Motil 24 2012 791 801
8. L.M. Begtrup, A.L. Engsbro, J. Kjeldsen, and et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome Clin Gastroenterol Hepatol 11 2013 956 962
9. M. Pimentel, L. Hwang, G.Y. Melmed, and et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy Dig Dis Sci 55 2010 145 149
10. O.S. Palsson, J. Baggish, and W.E. Whitehead Episodic nature of symptoms in irritable bowel syndrome Am J Gastroenterol 109 2014 1450 1460
11. S.J. Lewis, and K.W. Heaton Stool form scale as a useful guide to intestinal transit time Scand J Gastroenterol 32 1997 920 924
12. A.L. Engsbro, M. Simren, and P. Bytzer Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification Aliment Pharmacol Ther 35 2012 350 359
13. P.O. Vandvik, I. Wilhelmsen, C. Ihlebaek, and et al. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications Aliment Pharmacol Ther 20 2004 1195 1203
14. W.E. Whitehead, O.S. Palsson, R.R. Levy, and et al. Comorbidity in irritable bowel syndrome Am J Gastroenterol 102 2007 2767 2776
15. B. Spiegel, A. Strickland, B.D. Naliboff, and et al. Predictors of patient-assessed illness severity in irritable bowel syndrome Am J Gastroenterol 103 2008 2536 2543
16. P. Austin, S. Henderson, I. Power, and et al. An international Delphi study to assess the need for multiaxial criteria in diagnosis and management of functional gastrointestinal disorders J Psychosom Res 75 2013 128 134
17. A.C. Ford, P. Bercik, D.G. Morgan, and et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care Gastroenterology 145 2013 1262 1270
18. A.C. Ford, N.J. Talley, S.J. Veldhuyzen van Zanten, and et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 300 2008 1793 1805
19. P. Patel, P. Bercik, D.G. Morgan, and et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey Scand J Gastroenterol 50 2015 816 823
20. S.T. Menees, J. Kurlander, A. Goel, and et al. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS Gastroenterology 146 Suppl 2014 S194
21. N. Waugh, E. Cummins, P. Royle, and et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation Health Technol Assess 17 2013 1 211
22. U.C. Ghoshal, D. Srivastava, A. Verma, and et al. Tropical sprue in 2014: the new face of an old disease Curr Gastroenterol Rep 16 2014 391
23. D. Limsui, D.S. Pardi, M. Camilleri, and et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis Inflamm Bowel Dis 13 2007 175 181
24. S.A. Slattery, O. Niaz, Q. Azia, and et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea Aliment Pharmacol Ther 42 2015 3 11
25. M. Camilleri, K. Lasch, and W. Zhou Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome Am J Physiol Gastrointest Liver Physiol 303 2012 G775 G785
26. D.A. Drossman, D.C. McKee, R.S. Sandler, and et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome Gastroenterology 95 1988 701 708
27. A. Blewett, M. Allison, B. Calcraft, and et al. Psychiatric disorder and outcome in irritable bowel syndrome Psychosomatics 37 1996 155 160
28. D.A. Drossman Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 107 1999 41S 50S
29. C.Y. Francis, J. Morris, and P.J. Whorwell The irritable bowel scoring system: a simple method of monitoring IBS and its progress Aliment Pharmacol Therapeut 11 1997 395 402
30. E. Johannesson, M. Simrén, H. Strid, and et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial Am J Gastroenterol 106 2011 915 922
31. A.C. Ford, P. Moayyedi, B.E. Lacy, and et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation Am J Gastroenterol 109 Suppl 1 2014 S2 S26 quiz S27
32. C.J. Bijkerk, N.J. de Wit, J.W.M. Muris, and et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial BMJ 339 2009 b3154
33. J.R. Biesiekierski, E.D. Newnham, P.M. Irving, and et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial Am J Gastroenterol 106 2011 508 514
34. M.I. Vazquez-Roque, M. Camilleri, T. Smyrk, and et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function Gastroenterology 144 2013 903 911
35. P. Moayyedi, E.M. Quigley, B.E. Lacy, and et al. The effect of dietary intervention on irritable bowel syndrome: a systematic review Clin Transl Gastroenterol 2015 e107
36. E.P. Halmos, V.A. Power, S.J. Shepherd, and et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome Gastroenterology 146 2014 67 75
37. J.R. Biesiekierski, S.L. Peters, E.D. Newnham, and et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates Gastroenterology 145 2013 320 328
38. L. Böhn, S. Störsrud, T. Liljebo, and et al. Diet low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial Gastroenterology 149 2015 1399 1407.e2
39. R.W. Chapman, V. Stanghellini, M. Geraint, and et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome Am J Gastroenterol 108 2013 1508 1515
40. L. Chang, A. Lembo, and S. Sultan American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome Gastroenterology 147 2014 1149 1172 e2
41. J. Cuppoletti, J. Chakrabarti, K.P. Tewari, and et al. Differentiation between human ClC-2 and CFTR Cl- channels with pharmacological agents Am J Physiol Cell Physiol 307 2014 C479 C492
42. D.A. Drossman, W.D. Chey, J.F. Johanson, and et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies Aliment Pharmacol Therapeut 29 2009 329 341
43. W.D. Chey, D.A. Drossman, J.F. Johanson, and et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation Aliment Pharmacol Therapeut 35 2012 587 599
44. S. Rao, A.J. Lembo, S.J. Shiff, and et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation Am J Gastroenterol 107 2012 1714 1724
45. W.D. Chey, A.J. Lembo, B.J. Lavins, and et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety Am J Gastroenterol 107 2012 1702 1712
46. E.M.M. Quigley, J. Tack, W.D. Chey, and et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints Aliment Pharmacol Therapeut 37 2013 49 61
47. P. Miner, R. DeLuca, M. La Portilla, and et al. Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C) Am J Gastroenterol 2014 S541
48. A.S. Rao, B.S. Wong, M. Camilleri, and et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis Gastroenterology 139 2010 1549 1558
49. B. Lavo, M. Stenstam, A.L. Nielsen, and et al. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study Scand J Gastroenterol Suppl 130 1987 77 80
50. P.S. Efskind, T. Bernklev, and M.H. Vatn A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome Scand J Gastroenterol 31 1996 463 468
51. B.S. Wong, M. Camilleri, P. Carlson, and et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea Clin Gastroenterol Hepatol 10 2012 1009 1015
52. A. Bajor, H. Tornblom, M. Rudling, and et al. Increased colonic bile acid exposure: a relevant risk factor for symptoms and treatment in IBS Gut 64 2015 84 92
53. R. Khanna, J.K. MacDonald, and B.G. Levesque Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis J Clin Gastroenterol 48 2014 505 512
54. A.M. Borowiec, and R.N. Fedorak The role of probiotics in management of irritable bowel syndrome Curr Gastroenterol Rep 9 2007 393 400
55. L. O'Mahony, J. McCarthy, P. Kelly, and et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles Gastroenterology 128 2005 541 551
56. P.J. Whorwell, L. Altringer, J. Morel, and et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome Am J Gastroenterol 101 2006 1581 1590
57. A.C. Ford, E.M.M. Quigley, B.E. Lacy, and et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis Am J Gastroenterol 109 2014 1547 1561
58. M. Pimentel, A. Lembo, W.D. Chey, and et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation N Engl J Med 364 2011 22 32
59. A. Lembo, M. Pimentel, S.S. Rao, and et al. Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): results of the TARGET 3 study Am J Gastroenterol 2014 109
60. L. Chang, K. Tong, and V. Ameen Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences Am J Gastroenterol 105 2010 866 875
61. K. Garsed, J. Chernova, M. Hastings, and et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea Gut 63 2014 1617 1625
62. K. Matsueda, S. Harasawa, M. Hongo, and et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome Scand J Gastroenterol 43 2008 1202 1211
63. P.R. Wade, J.M. Palmer, S. McKenney, and et al. Modulation of gastrointestinal function by MuDelta, a mixed micro opioid receptor agonist/ micro opioid receptor antagonist Br J Pharmacol 167 2012 1111 1125
64. A.J. Lembo, B.E. Lacy, M.J. Zuckerman, and et al. Eluxadoline treatment for irritable bowel syndrome with diarrhea N Engl J Med 374 2016 242 253
65. A.C. Ford, E.M. Quigley, B.E. Lacy, and et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis Am J Gastroenterol 109 2014 1350 1365
66. H. Vahedi, S. Merat, S. Momtahen, and et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome Aliment Pharmacol Ther 27 2008 678 684
67. O. Leri, S. Tubili, F.G. De Rosa, and et al. Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate Inflammopharmacology 5 1997 153 158
68. C. Lam, W. Tan, M. Leighton, and et al. A multi-centre, parallel group, randomised placebo controlled trial of mesalazine for treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D) Gastroenterology 146 Suppl 1 2014 S123 S124
69. G. Barbara, C. Cremon, L. Bellacosa, and et al. Randomized placebo controlled multicenter trial of mesalazine in patients with irritable bowel syndrome (IBS) Gastroenterology 146 Suppl 1 2014 S124
70. E. Manheimer, L.S. Wieland, K. Cheng, and et al. Acupuncture for rritable bowel syndrome: systematic review and meta-analysis Am J Gastroenterol 107 2012 835 847 quiz 848
71. N.J. Talley, A.L. Weaver, A.R. Zinsmeister, and et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders Am J Epidemiol 136 1992 165 177
72. R.S. Choung, G.R. Locke, C.D. Schleck, and et al. Cumulative incidence of chronic constipation: a population-based study 1988-2003 Aliment Pharmacol Ther 26 2007 1521 1588
73. N.C. Suares, and A.C. Ford Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis Am J Gastroenterology 106 2011 1582 1591
74. J.Y. Chang, G.R. Locke, C.D. Schleck, and et al. Risk factors for chronic constipation and a possible role of analgesics Neurogastroenterol Motil 19 2007 905 911
75. L. Dukas, W.C. Willett, and E.L. Giovannucci Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women Am J Gastroenterology 98 2003 1790 1796
76. J.F. Johanson, and J. Kralstein Chronic constipation: a survey of the patient perspective Aliment Pharmacol Ther 25 2007 599 608
77. A.E. Bharucha, J.H. Pemberton, and G.R. Locke American Gastroenterological Association technical review on constipation Gastroenterology 144 2013 218 238
78. K. Tantiphlachiva, P. Rao, A. Attaluri, and et al. Digital rectal examination is a useful tool for identifying patients with dyssynergia Clin Gastroenterol Hepatol 8 2010 955 960
79. G. Chiarioni, S.M. Kim, and W.E. Whitehead Dyssynergic defecation can be diagnosed by questionnaire and physical examination Gastroenterology 144 2013 S366
80. S. Chaussade, H. Roche, A. Khyari, and et al. Measurement of colonic transit time: description and validation of a new method Gastroenterol Clin Biol 10 1986 385 389
81. A.M. Metcalf, S.F. Phillips, A.R. Zinsmeister, and et al. Simplified assessment of segmental colonic transit Gastroenterology 92 1987 40 47
82. T. Stivland, M. Camilleri, M. Vassallo, and et al. Scintigraphic measurement of regional gut transit in idiopathic constipation Gastroenterology 101 1991 107 115
83. M. Minguez, B. Herreros, V. Sanchiz, and et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation Gastroenterology 126 2004 57 62
84. E.J. Videlock, A. Lembo, and F. Cremonini Diagnostic testing for dyssynergic defecation in chronic constipation: meta-analysis Neurogastroenterol Motil 25 2013 509 520
85. W. Ostwani, J. Dolan, and Y. Elitsur Familial clustering of habitual constipation: a prospective study in children from West Virginia J Pediatr Gastroenterol Nutr 50 2010 287 289
86. A.O. Chan, K.F. Lam, W.M. Hui, and et al. Influence of positive family history on clinical characteristics of functional constipation Clin Gastroenterol Hepatol 5 2007 197 200
87. M. Camilleri, M.I. Vazquez-Roque, P. Carlson, and et al. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders Neurogastroenterol Motil 23 2011 995 999
88. A. Beyder, A. Mazzone, P.R. Strege, and et al. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome Gastroenterology 146 2014 1659 1668
89. P. Kocaay, O. Egritas, and B. Dalgic Normal defecation pattern, frequency of constipation and factors related to constipation in Turkish children 0-6 years old Turk J Gastroenterol 22 2011 369 375
90. K.S. Ip, W.T. Lee, J.S. Chan, and et al. A community-based study of the prevalence of constipation in young children and the role of dietary fibre Hong Kong Med J 11 2005 431 436
91. M.F. Chan, and Y.L. Chan Investigating factors associated with functional constipation of primary school children in Hong Kong J Clin Nurs 19 2010 3390 3400
92. J.M. Chung, S.D. Lee, D.I. Kang, and et al. An epidemiologic study of voiding and bowel habits in Korean children: a nationwide multicenter study Urology 76 2010 215 219
93. E.R. Wald, L.C. Di, L. Cipriani, and et al. Bowel habits and toilet training in a diverse population of children J Pediatr Gastroenterol Nutr 48 2009 294 298
94. K. Murakami, S. Sasaki, H. Okubo, and et al. Association between dietary fiber, water and magnesium intake and functional constipation among young Japanese women Eur J Clin Nutr 61 2007 616 622
95. S. Nakaji, S. Tokunaga, J. Sakamoto, and et al. Relationship between lifestyle factors and defecation in a Japanese population Eur J Nutr 41 2002 244 248
96. A.J. Daley, C. Grimmett, L. Roberts, and et al. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial Int J Sports Med 29 2008 778 782
97. R.J. Young, L.E. Beerman, and J.A. Vanderhoof Increasing oral fluids in chronic constipation in children Gastroenterol Nurs 21 1998 156 161
98. N. Manabe, B.S. Wong, M. Camilleri, and et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort Neurogastroenterol Motil 22 2010 293-e82
99. S.S. Rao, B. Kuo, R.W. McCallum, and et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation Clin Gastroenterol Hepatol 7 2009 537 544
100. H. Mertz, B. Naliboff, and E. Mayer Physiology of refractory chronic constipation Am J Gastroenterol 94 1999 609 615
101. S. Nullens, T. Nelsen, M. Camilleri, and et al. Regional colon transit in patients with dys-synergic defaecation or slow transit in patients with constipation Gut 61 2012 1132 1139
102. P.G. Dinning, N. Zarate, L.M. Hunt, and et al. Pancolonic spatiotemporal mapping reveals regional deficiencies in, and disorganization of colonic propagating pressure waves in severe constipation Neurogastroenterol Motil 22 2010 e340 e349
103. C. Shekhar, P.J. Monaghan, J. Morris, and et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin Gastroenterology 145 2013 749 757
104. C.H. Knowles, S.M. Scott, A. Wellmer, and et al. Sensory and autonomic neuropathy in patients with idiopathic slow-transit constipation Br J Surg 86 1999 54 60
105. S. Krishnamurthy, M.D. Schuffler, C.A. Rohrmann, and et al. Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus Gastroenterology 88 1985 26 34
106. K. Tzavella, R.L. Riepl, A.G. Klauser, and et al. Decreased substance P levels in rectal biopsies from patients with slow transit constipation Eur J Gastroenterol Hepatol 8 1996 1207 1211
107. C. Cortesini, F. Cianchi, A. Infantino, and et al. Nitric oxide synthase and VIP distribution in enteric nervous system in idiopathic chronic constipation Dig Dis Sci 40 1995 2450 2455
108. M. El-Salhy, O. Norrgard, and S. Spinnell Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation Scand J Gastroenterol 34 1999 1007 1011
109. K.M. Sanders, S.M. Ward, and S.D. Koh Interstitial cells: regulators of smooth muscle function Physiol Rev 94 2014 859 907
110. C.L. He, L. Burgart, L. Wang, and et al. Decreased interstitial cell of cajal volume in patients with slow-transit constipation Gastroenterology 118 2000 14 21
111. G.L. Lyford, C.L. He, E. Soffer, and et al. Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation Gut 51 2002 496 501
112. A. Wald, J.P. Hinds, and B.J. Caruana Psychological and physiological characteristics of patients with severe idiopathic constipation Gastroenterology 97 1989 932 937
113. W. Ashraf, F. Park, J. Lof, and et al. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation Am J Gastroenterology 91 1996 26 32
114. I.C. Hobbis, G. Turpin, and N.W. Read Abnormal illness behaviour and locus of control in patients with functional bowel disorders Br J Health Psychol 8 2003 393 408
115. A.G. Klauser, W.A. Voderholzer, C.A. Heinrich, and et al. Behavioral modification of colonic function. Can constipation be learned? Dig Dis Sci 35 1990 1271 1275
116. P. Moayyedi, E.M. Quigley, B.E. Lacy, and et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis Am J Gastroenterol 109 2014 1367 1374
117. W.D. Chey The role of food in the functional gastrointestinal disorders: introduction to a manuscript series Am J Gastroenterol 108 2013 694 697
118. F.A. Lederle, D.L. Busch, K.M. Mattox, and et al. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose Am J Med 89 1990 597 601
119. A.P. Passmore, K. Wilson-Davies, C. Stoker, and et al. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fibre combination BMJ 307 1993 769 771
120. J.A. Dipalma, M.V. Cleveland, J. McGowan, and et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation Am J Gastroenterol 102 2007 1436 1441
121. S. Chaussade, and M. Minić Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation Aliment Pharmacol Ther 17 2003 165 172
122. A. Attar, M. Lémann, A. Ferguson, and et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation Gut 44 1999 226 230
123. W. Voskuijl, F. de Lorijn, W. Verwijs, and et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial Gut 53 2004 1590 1594
124. J.H. Xing, and E.E. Soffer Adverse effects of laxatives Dis Colon Rectum 44 2001 1201 1209
125. J. Frexinos, G. Staumont, J. Fioramonti, and et al. Effects of sennosides on colonic myoelectrical activity in man Dig Dis Sci 34 1989 214 219
126. J.C. Schang, M. Hémond, M. Hébert, and et al. Changes in colonic myoelectric spiking activity during stimulation by bisacodyl Can J Physiol Pharmacol 64 1986 39 43
127. N. Ikarashi, K. Baba, T. Ushiki, and et al. The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages Am J Physiol 301 2011 G887 G895
128. M.A. Kamm, S. Mueller-Lissner, A. Wald, and et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation Clin Gastroenterol Hepatol 9 2011 577 583
129. S. Mueller-Lissner, M.A. Kamm, A. Wald, and et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation Am J Gastroenterol 105 2010 897 903
130. J.F. Johanson, and R. Ueno Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety Aliment Pharmacol Ther 25 2007 1351 1361
131. C.F. Barish, D. Drossman, J.F. Johanson, and et al. Efficacy and safety of lubiprostone in patients with chronic constipation Dig Dis Sci 55 2010 1090 1097
132. J.F. Johanson, D. Morton, J. Geenen, and et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation Am J Gastroenterol 103 2008 170 177
133. A.J. Lembo, H.A. Schneier, S.J. Shiff, and et al. Two randomized trials of linaclotide for chronic constipation N Engl J Med 365 2011 527 536
134. P.B. Miner, R. Surowitz, R. Fogel, and et al. Plecanatide, a novel guanylate cyclase-C (GC-C) receptor agonist, is efficacious and safe in patients with chronic idiopathic constipation (CIC): results from a 951 patient, 12 week, multi-center trial Gastroenterology 144 2013 S163
135. M. Simren, A. Bajor, P.G. Gillberg, and et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. Placebo in patients with chronic idiopathic constipation: a doubleblind study Aliment Pharmacol Ther 34 2011 41 50
136. B.S. Wong, M. Camilleri, S. McKinzie, and et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation Am J Gastroenterol 106 2011 2154 2164
137. W.D. Chey, M. Camilleri, L. Chang, and et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation Am J Gastroenterol 106 2011 1803 1812
138. J.R. Grider, A.E. Foxx-Orenstein, and J.G. Jin 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine Gastroenterology 115 1998 370 380
139. E.P. Bouras, M. Camilleri, D.D. Burton, and et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder Gastroenterology 120 2001 354 360
140. C.M. Prather, M. Camilleri, A.R. Zinsmeister, and et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome Gastroenterology 118 2000 463 468
141. J.F. Johanson, A. Wald, G. Tougas, and et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial Clin Gastroenterol Hepatol 2 2004 796 805
142. M.A. Kamm, S. Müller-Lissner, N.J. Talley, and et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study Am J Gastroenterol 100 2005 362 372
143. J. Tack, O.M. van, G. Beyens, and et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives Gut 58 2009 357 365
144. E.M.M. Quigley, L. Vandeplassche, R. Kerstens, and et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study Aliment Pharmacol Ther 29 2009 315 328
145. A. Attaluri, R. Donahoe, J. Valestin, and et al. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation Aliment Pharmacol Ther 33 2011 822 828
146. C.-W. Cheng, Z.-X. Bian, L.-X. Zhu, and et al. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation Am J Gastroenterol 106 2011 120 129
147. A. Chmielewska, and H. Szajewska Systematic review of randomised controlled trials: probiotics for functional constipation World J Gastroenterol 16 2010 69 75
148. C.K. Porter, R. Gormley, D.R. Tribble, and et al. The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population Am J Gastroenterol 106 2011 130 138
149. D. Roshandel, M. Rezailashkajani, S. Shafaee, and et al. Symptom patterns and relative distribution of functional bowel disorders in 1,023 gastroenterology patients in Iran Int J Colorectal Dis 21 2006 814 825
150. M. Schmulson, O. Ortíz, M. Santiago-Lomeli, and et al. Frequency of functional bowel disorders among healthy volunteers in Mexico City Dig Dis 24 2006 342 347
151. Y.F. Zhao, X.J. Guo, Z.S. Zhang, and et al. Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China PLoS One 7 2012 e43749
152. M. Sorouri, M.A. Pourhoseingholi, M. Vahedi, and et al. Functional bowel disorders in Iranian population using Rome III criteria Saud J Gastroenterol 16 2010 154 160
153. F.-Y. Chang, P.-H. Chen, T.-C. Wu, and et al. Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria Asia Pac J Clin Nutr 21 2012 594 600
154. L.J. O'Donnell, J. Virjee, and K.W. Heaton Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate BMJ 300 1990 439 440
155. G.F. Longstreth, W.G. Thompson, W.D. Chey, and et al. Functional bowel disorders Gastroenterology 130 2006 1480 1491
156. S.J. Vanner, W.T. Depew, W.G. Paterson, and et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome Am J Gastroenterol 94 1999 2912 2917
157. M.E. Money, and M. Camilleri Review: Management of postprandial diarrhea syndrome Am J Med 125 2012 538 544
158. D.J. Gracie, J.S. Kane, S. Mumtaz, and et al. Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea Neurogastroenterol Motil 24 2012 983-e538
159. J. Tack Functional diarrhea Gastroenterol Clin North Am 41 2012 629 637
160. G. Bazzocchi, J. Ellis, J. Villanueva-Meyer, and et al. Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations Gastroenterology 101 1991 1298 1306
161. M.G. Choi, M. Camilleri, M.D. O'Brien, and et al. A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia Am J Gastroenterol 92 1997 297 302
162. B. Zanini, C. Ricci, F. Bandera, and et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak Am J Gastroenterol 107 2012 891 899
163. S.D. Parry, R. Stansfield, D. Jelley, and et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study Am J Gastroenterol 98 2003 1970 1975
164. P.A. Cann, N.W. Read, J. Cammack, and et al. Psychological stress and the passage of a standard meal through the stomach and small intestine in man Gut 24 1983 236 240
165. N. Hovdenak Loperamide treatment of the irritable bowel syndrome Scand J Gastroenterol 130 Suppl 1987 81 84
166. F. Fernández-Bañares, M. Rosinach, M. Piqueras, and et al. Randomised clinical trial: colestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea Aliment Pharmacol Ther 41 2015 1132 1140
167. J. Serra, F. Azpiroz, and J.R. Malagelada Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome Gut 48 2001 14 19
168. Y. Zhu, X. Zheng, Y. Cong, and et al. Bloating and distention in irritable bowel syndrome: the role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency Am J Gastroenterol 108 2013 1516 1525
169. R.S. Sandler, W.F. Stewart, J.N. Liberman, and et al. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact Dig Dis Sci 45 2000 1166 1171
170. A.K. Tuteja, N.J. Talley, S.K. Joos, and et al. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders Am J Gastroenterol 103 2008 1241 1248
171. X. Jiang, G.R. Locke, R.S. Choung, and et al. Prevalence and risk factors for abdominal bloating and visible distention: a population-based study Gut 57 2008 756 763
172. T. Lembo, B. Naliboff, J. Munakata, and et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome Am J Gastroenterol 94 1999 1320 1326
173. L. Chang, O.Y. Lee, B. Naliboff, and et al. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome Am J Gastroenterol 96 2001 3341 3347
174. Y. Ringel, R.E. Williams, L. Kaulan, and et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome Clin Gastroenterol Hepatol 7 2009 68 72 quiz 73
175. W.G. Thompson Gender differences in irritable bowel symptoms Euro J Gastroenterol & Hepatol 9 1997 299 302
176. O.Y. Lee, E.A. Mayer, M. Schmulson, and et al. Gender-related differences in IBS symptoms Am J Gastroenterol 96 2001 2184 2193
177. Y.F. Zhao, X.Q. Ma, R. Wang, and et al. Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the Systematic Investigation of Gastrointestinal Diseases in China (SILC) Aliment Pharmacol Ther 34 2011 1020 1029
178. D.G. Maxton, D.F. Martin, P.J. Whorwell, and et al. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms Gut 32 1991 662 664
179. D.G. Maxton, and P.J. Whorwell Abdominal distension in irritable bowel syndrome: the patient's perception Eur Hepatol 4 1992 241 243
180. M.J. Lewis, B. Reilly, L.A. Houghton, and et al. Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome Gut 48 2001 216 220
181. A.C. Dukowicz, B.E. Lacy, and G.M. Levine Small intestinal bacterial overgrowth: a comprehensive review Gastroenterol Hepatol 3 2007 112 122
182. A. Accarino, F. Perez, F. Azpiroz, and et al. Abdominal distention results from caudo-ventral redistribution of contents Gastroenterology 136 2009 1544 1551
183. A. Agrawal, L.A. Houghton, R. Lea, and et al. Bloating and distention in irritable bowel syndrome: the role of visceral sensation Gastroenterology 134 2008 1882 1889
184. A. Agrawal, L.A. Houghton, B. Reilly, and et al. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit Am J Gastroenterology 104 2009 1998 2004
185. J.E. Bernstein, and A.M. Kasich A double-blind trial of simethicone in functional disease of the upper gastrointestinal tract J Clin Pharmacol 14 1974 617 623
186. T.G. Ganiats, W.A. Norcross, A.L. Halverson, and et al. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance J Fam Pract 39 1994 441 445
187. J.H. Liu, G.H. Chen, H.Z. Yeh, and et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial J Gastroenterol 32 1997 765 768
188. G. Cappello, M. Spezzaferro, L. Grossi, and et al. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial Dig Liver Dis 39 2007 530 536
189. B.E. Lacy, R. Schey, S.J. Shiff, and et al. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial PLoS One 10 2015 e0134349
190. D.A. Drossman, B.B. Toner, W.E. Whitehead, and et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders Gastroenterology 125 2003 19 31
191. J. Tack, D. Broekaert, B. Fischler, and et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome Gut 55 2006 1095 1103
192. M.P. Caldarella, J. Serra, F. Azpiroz, and et al. Prokinetic effects in patients with intestinal gas retention Gastroenterology 122 2002 1748 1755
193. A. Accarino, F. Perez, F. Azpiroz, and et al. Intestinal gas and bloating: effect of prokinetic stimulation Am J Gastroenterol 103 2008 2036 2042
194. J. Gaertner, W. Siemens, M. Camilleri, and et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review J Clin Gastroenterol 49 2015 9 16
195. E. Kalso, J.E. Edwards, R.A. Moore, and et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety Pain 112 2004 372 380
196. N.P. Sykes The relationship between opioid use and laxative use in terminally ill cancer patients Palliat Med 12 1998 375 382
197. M. Camilleri Opioid-induced constipation: challenges and therapeutic opportunities Am J Gastroenterol 106 2011 835 842
198. T.J. Bell, S.J. Panchal, C. Miaskowski, and et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1) Pain Med 10 2009 35 42
199. P. Holzer, S.H. Ahmedzai, N. Niederle, and et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management J Opioid Manag 5 2009 145 151
200. A. Caraceni, G. Hanks, S. Kaasa, and et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC Lancet Oncol 13 2012 e58 e68
201. C.E. Sloots, A. Rykx, M. Cools, and et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation Dig Dis Sci 55 2010 2912 2921
202. D.M. Brenner, and W.D. Chey An evidence-based review of novel and emerging therapies for constipation in patients taking opioid analgesics Am J Gastroenterol 2 2014 38 46
203. M. Liu, and E. Wittbrodt Low-dose oral naloxone reverses opioid-induced constipation and analgesia J Pain Symptom Manage 23 2002 48 53
204. N.P. Sykes An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer Palliat Med 10 1996 135 144
205. J. Thomas, S. Karver, G.A. Cooney, and et al. Methylnaltrexone for opioid-induced constipation in advanced illness N Engl J Med 358 2008 2332 2343
206. FDA approves Relistor for opioid-induced constipation. 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116885.htm. Accessed October 5, 2015.
207. M. Camilleri Alvimopan, a selective peripherally acting mu-opioid antagonist Neurogastroenterol Motil 17 2005 157 165
208. W. Chey, L. Webster, M. Sostek, and et al. Naloxegol for opioid-induced constipation in patients with non-cancer pain N Engl J Med 370 2014 2387 2396